Zoetis Inc. $ZTS Shares Purchased by California Public Employees Retirement System

California Public Employees Retirement System increased its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 39.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,654,423 shares of the company’s stock after buying an additional 466,299 shares during the quarter. California Public Employees Retirement System owned 0.38% of Zoetis worth $242,075,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Zoetis by 1.0% during the third quarter. Vanguard Group Inc. now owns 42,306,764 shares of the company’s stock worth $6,190,326,000 after acquiring an additional 419,777 shares during the last quarter. Norges Bank purchased a new position in shares of Zoetis in the 2nd quarter valued at approximately $809,491,000. Brown Advisory Inc. boosted its stake in Zoetis by 5.7% in the 2nd quarter. Brown Advisory Inc. now owns 4,659,371 shares of the company’s stock worth $726,629,000 after purchasing an additional 250,829 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its stake in Zoetis by 14.6% in the 3rd quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 4,312,779 shares of the company’s stock worth $631,046,000 after purchasing an additional 550,859 shares in the last quarter. Finally, Alliancebernstein L.P. grew its position in Zoetis by 13.3% during the 3rd quarter. Alliancebernstein L.P. now owns 4,241,357 shares of the company’s stock worth $620,595,000 after purchasing an additional 496,320 shares during the last quarter. 92.80% of the stock is currently owned by hedge funds and other institutional investors.

Zoetis Trading Up 0.1%

Shares of Zoetis stock opened at $115.62 on Monday. The stock has a market cap of $48.81 billion, a PE ratio of 19.21, a price-to-earnings-growth ratio of 1.76 and a beta of 0.95. The firm has a fifty day moving average price of $125.34 and a 200 day moving average price of $131.58. Zoetis Inc. has a 1 year low of $114.47 and a 1 year high of $172.23. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94.

Zoetis (NYSE:ZTS) last posted its quarterly earnings results on Thursday, February 12th. The company reported $1.48 EPS for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The firm’s revenue was up 3.0% on a year-over-year basis. During the same period in the prior year, the company earned $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities research analysts predict that Zoetis Inc. will post 6.07 earnings per share for the current year.

Zoetis Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. This represents a $2.12 annualized dividend and a yield of 1.8%. The ex-dividend date of this dividend is Monday, April 20th. Zoetis’s dividend payout ratio (DPR) is 35.22%.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. KeyCorp initiated coverage on shares of Zoetis in a report on Thursday, November 20th. They issued a “sector weight” rating for the company. The Goldman Sachs Group raised shares of Zoetis to a “buy” rating in a report on Monday, December 15th. Morgan Stanley set a $160.00 target price on Zoetis in a research report on Thursday, December 18th. Wall Street Zen raised Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Piper Sandler reissued a “neutral” rating and issued a $135.00 price objective (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Six investment analysts have rated the stock with a Buy rating and eight have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.